Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4)

Trial Profile

Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLY-3+
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 24 May 2016 Results (pooled analysis of this and other study, n = 98) assessing safety and efficacy of daclatasvir Plus sofosbuvir with or without ribavirin in patients with advanced fibrosis or cirrhosis presented at the Digestive Disease Week 2016.
    • 24 May 2016 Results of a sub-analysis (n=37) presented at the Digestive Disease Week 2016.
    • 17 Apr 2016 Pooled safety and efficacy analysis of ALLY-3 and ALLY-3+ studies (n=168) were presented at The International Liver Congress 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top